To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
46 Current news of MediGene
rss
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
27-01-2012
MediGene AG continues clinical development of its drug candidate RhuDex® by initiating a clinical formulation study. The trial objective is to develop an optimized oral formulation of the active substance suitable for the treatment of chronic diseases. The results of this formulation study ...
MediGene Receives Authorization for the Clinical Formulation Study of RhuDex
01-11-2011
MediGene AG announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) granted the authorization of the planned clinical formulation study of RhuDex®, a drug candidate being developed for the treatment of rheumatoid arthritis. The objective of the RapidFACTTM ...
MediGene and Pharmanova Sign Agreement for the Commercialization of Veregen in Southeastern Europe
08-09-2011
MediGene AG has signed an exclusive license and supply agreement with Pharmanova d.o.o. for the supply and commercialization of Veregen® ointment in Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania, for the treatment of genital warts. MediGene is entitled ...
MediGene reports positive results for the first half of 2011 and confirms forecast for the year
Increase in total revenue (from continued operations and discontinued operations) by 18% to EUR 29.6 million (6M 2010: EUR 25.2 million)
04-08-2011
MediGene AG generated total revenue (from continued operations and discontinued operations) of EUR 29.6 million in the first half of the 2011 fiscal year (6M 2010: EUR 25.2 million). This revenue consists primarily of product sales from the commercialization of the drugs Eligard® and Veregen® ...
MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform
Examination of product candidates for the prevention of HPV-associated diseases
03-06-2011
MediGene AG and The Johns Hopkins University, Baltimore, USA, have agreed to collaborate in the field of AAVLP vaccine technology. The objective of this collaboration is to test vaccine candidates derived from the AAVLP program for the prevention of HPV-associated cancer types, and in so ...
MediGene Signs Veregen Commercialization Agreement with SynCore Bio in Taiwan
24-05-2011
MediGene AG has signed an exclusive license and supply agreement with SynCore Bio, a subsidiary of the Sinphar Group, for the commercialization and marketing of Veregen® ointment in Taiwan for the treatment of genital warts. MediGene will supply Sinphar with API, Sinphar will produce the ...
MediGene and Triton Pharma Sign Partnership Agreement for the Commercialization of Veregen in Canada
21-04-2011
The biotech company MediGene AG has signed an exclusive license and supply agreement with the Canadian company Triton Pharma Inc. for the supply and commercialization of Veregen® ointment for the treatment of genital warts in Canada. Triton will be responsible for the drug approval procedure ...
MediGene and Will-Pharma Sign Agreement for the Commercialization of Veregen in Benelux
15-03-2011
MediGene AG has signed an exclusive license and supply agreement with Will-Pharma for the commercialization and marketing of Veregen® ointment in Belgium, the Netherlands and Luxembourg. Will-Pharma will market, promote and distribute the drug for the treatment of genital warts. Further ...
MediGene Completes the Transfer of Eligard Rights for EU Countries to Astellas
04-03-2011
MediGene AG announced that exclusive European rights to the cancer drug Eligard® have been transferred to Astellas Pharma Europe Ltd., with effect from March 1, 2011. This will trigger a second milestone payment from Astellas to MediGene, amounting to EUR 15 million, as agreed in the July ...
MediGene and Pierre Fabre Sign Agreement for the Commercialization of Veregen in Mexico, Central America, Venezuela and Colombia
23-02-2011
MediGene AG has signed a license and supply agreement with Pierre Fabre Medicament, for the supply and marketing of Veregen® ointment in Mexico, Central America, Venezuela and Colombia. Pierre Fabre will be responsible for all approval procedures in the concerned countries and will promote ...
Netmeeting
